AN2 Therapeutics(US:ANTX)2024-08-13 20:06Financial Performance - Cash, cash equivalents, and investments totaled $104.5 million as of June 30, 2024, expected to fund operations through 2027[1] - Net loss for Q2 2024 was $14.4 million, an improvement from a net loss of $15.8 million in Q2 2023[7] - Other income for Q2 2024 was $1.4 million, up from $0.8 million in Q2 2023, attributed to increased interest income[6] - Total operating expenses for Q2 2024 were $15.9 million, slightly down from $16.6 million in Q2 2023[11] Research and Development - Research and Development (R&D) expenses for Q2 2024 were $12.1 million, a decrease of 10.3% from $13.5 million in Q2 2023[5] - The company plans to advance two development programs into clinical trials in 2025, including AN2-502998 for chronic Chagas disease and epetraborole for melioidosis[2] - The Phase 2 part of the EBO-301 study was terminated, although it met its primary objective regarding a novel patient-reported outcome tool[3] - The company published new data on epetraborole's efficacy against M. abscessus, indicating its potential as an important therapy for lung disease[4] Administrative Expenses - General and Administrative (G&A) expenses increased to $3.7 million in Q2 2024 from $3.1 million in Q2 2023, reflecting higher personnel-related expenses[5] Product Pipeline - The company has a pipeline of boron-based compounds targeting high unmet needs in infectious disease and oncology[2]